Sclerosing Epithelioid Fibrosarcoma?
Sclerosing Epithelioid Fibrosarcoma (SEF) is a rare cancer of significant unmet need. SEF is a soft tissue sarcoma of children, teenagers and adults that can also arise from the kidney, bone and other locations.
Treatment is primarily surgical when not metastatic; however, most cases are or become metastatic. Effective chemotherapy regimens for widespread metastases are not yet established, although doxorubicin and irinotecan have been anecdotally suggested to bring short-term benefit.
Innovative new therapies are urgently needed for curative-intent treatments.
No progress in developing new targeted therapies for SEF will occur until essential laboratory tools are created for broad sharing and a centralized knowledge base for SEF is formed.
There are currently:
NO reported cell lines
NO mouse xenograft models and
NO mouse transgenic models
While the role of immunotherapy is undefined, this approach could be tested if laboratory tools were available.
Has there been
Can You Help as a Community Scientist?
By working in partnership to create and implement a strategic roadmap together we can achieve the overall goal of seeding the development of treatment options.